For Immediate Release
Pi Health Appoints Dr. Alex Morozov as Chief Medical Officer
Appointment of physician-scientist with deep experience in oncology trials follows $30M Series A financing and launch of groundbreaking cancer hospital in India
CAMBRIDGE, Mass. — Aug. 8, 2024 — Pi Health, an oncology clinical trial and research technology company, today announced the appointment of Alex Morozov, M.D., Ph.D., as its first Chief Medical Officer. Dr. Morozov brings extensive firsthand experience, including 14 years overseeing hundreds of oncology trials at major companies like Pfizer, Bristol Myers Squibb and Exelixis, where he contributed to the global approvals of multiple therapies such as Bavencio, Lorbrena, Opdivo/Yervoy and Cabometyx.
The addition of Dr. Morozov follows Pi Health’s recent $30M Series A financing and the launch of its state-of-the-art cancer hospital in Hyderabad, India. The hospital serves as a model for integrating research and care delivery powered by the company’s proprietary end-to-end technology platform. With a growing network of health system partnerships spanning the US, Brazil, Australia and India, Pi Health aims to accelerate the development of practice-changing therapies while democratizing access to clinical trials globally.
“We are thrilled to welcome Alex to the Pi Health team,” said Geoff Kim, M.D., co-founder and CEO of Pi Health. “His unique background as a physician-scientist, drug developer and digital health innovator aligns with our mission to bridge the gap between clinical research and care delivery. Alex’s leadership will be instrumental as we scale our platform and expand our partnerships worldwide to bring clinical trials to diverse patient populations.”
Before joining Pi Health, Dr. Morozov served as SVP and Head of Clinical Development and Clinical Pharmacology at Exelixis, overseeing a portfolio spanning first-in-human and late-phase programs in oncology. At BMS, he led the clinical team overseeing the Opdivo-Yervoy portfolio, spearheaded several clinical trial innovation pilots, and built the first Digital Health team at BMS, overseeing a portfolio of digital programs across therapeutic areas leveraging technologies like remote monitoring, digital biomarkers and AI/ML to improve patient outcomes.
“I am excited to join Pi Health in its mission to integrate clinical research and clinical practice on a global scale,” said Dr. Morozov. “Pi Health’s collaborations with health systems and commitment to diversity represents a paradigm shift in how we develop and access life-saving treatments. I look forward to partnering with our investigators, academic institutions and biopharma drug developers to leverage our end-to-end platform and generative AI to improve speed, quality and efficiency of drug development.”
Dr. Morozov’s expertise spans early and late-phase trials, clinical pharmacology, digital innovation, process optimization and global execution. He has authored numerous high-impact publications and holds a B.S. from MIT and an M.D. and Ph.D. from Albert Einstein College of Medicine. He trained in internal medicine at Columbia and in medical oncology at MSKCC.
“Alex deeply understands the challenges and opportunities at the intersection of drug development, patient care and technology,” said Bobby Reddy, MD, co-founder and COO of Pi Health. “His experience driving health equity in trials and reducing site burden make him a natural fit for the job. We are confident Alex will help us deliver on the promise of our platform to accelerate breakthroughs for all patients.”
The appointment is the latest example of Pi Health’s commitment to building a world-class team of talent to revolutionize the clinical research ecosystem. By bridging the worlds of drug development and digital innovation, the company aims to make it possible for every patient, regardless of geography, to access world-class clinical care and research.
About Pi Health
Pi Health is an oncology clinical trial and research technology company committed to transforming global access to innovative medicines. Founded in 2021, the team is focused on empowering life science companies to develop medicines faster and reach diverse patient populations via a proprietary end-to-end clinical trial platform. The organization’s health system partnerships include oncology centers across the US, Brazil, Australia and India, as well as a new cancer hospital in Hyderabad, India, which embodies Pi Health’s mission to bring modern, efficient and equitable trials to populations worldwide. To learn more, please visit pihealth.ai
For more information, please contact press@pihealth.ai
